The clinical potential of antiangiogenic fragments of extracellular matrix proteins

British Journal of Cancer

Volumn 93, Issue 9, 2005, Pages 967-972

  Clamp, A R ^a   Jayson, G C ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTELLIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ARRESTEN; CANSTATIN; ENDOREPELLIN; ENDOSTATIN; FUMAGILLOL CHLOROACETYLCARBAMATE; GELATINASE A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTEGRIN; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; PEPTIDE FRAGMENT; RESTIN; SCLEROPROTEIN; SEMAXANIB; THROMBOSPONDIN 1; TUMSTATIN; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONCENTRATION RESPONSE; DOSE CALCULATION; DRUG DESIGN; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; GENE DELETION; HUMAN; IMMUNOGENICITY; LUNG NON SMALL CELL CANCER; METASTASIS; METHODOLOGY; NEUROENDOCRINE TUMOR; NONHUMAN; PANCREAS TUMOR; PATIENT SELECTION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SHORT SURVEY; SIGNAL TRANSDUCTION; THROMBOCYTE COUNT; TREATMENT OUTCOME; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; COLLAGEN TYPE XVIII; ENDOSTATINS; EXTRACELLULAR MATRIX PROTEINS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 27644520996     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602820     Document Type: Short Survey

References (45)

1. Abdollahi A, Hahnfeldt P, Maercker C, Gröne H-J, Debus J, Ansorge W, Folkman J, Hlatky L, Huber PE (2004) Endostatin's antiangiogenic signaling network. Mol Cell 13: 649-663
2. Abdollahi A, Lipson KE, Sckell A, Zieher H, Klenke F, Poerschke D, Roth A, Han X, Krix M, Bischof M, Hahnfeldt P, Grone H-J, Debus J, Hlatky L, Huber PE (2003) Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res 63: 8890-8898
3. Bix G, Fu J, Gonzalez EM, Macro L, Barker A, Campbell S, Zutter MM, Santoro SA, Kim JK, Reed CC, Iozzo RV (2004) Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through α2β1 integrin. J Cell Biol 166: 97-109
4. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407: 249-257
5. Cline EI, Bicciato S, DiBello C, Lingen MW (2002) Prediction of in vivo synergistic activity of antiangiogenic compounds by gene expression profiling. Cancer Res 62: 7143-7148
6. Davis DW, Shen Y, Mullani NA, Wen S, Herbst RS, O'Reilly M, Abbruzzese JL, McConkey DJ (2004) Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors. Clin Cancer Res 10: 33-42
7. Eder JP, Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP, Shulman LN, Proper J, Kirvan M, Rattner B, Connors S, Keogan MT, Janicek MJ, Fogler WE, Schnipper L, Kinchla N, Sidor C, Philips E, Folkman J, Kufe DW (2002) Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 20: 3772-3784
8. Feldman AL, Alexander Jr HR, Yang JC, Linehan WM, Eyler RA, Miller MS, Steinberg SM, Libutti SK (2002) Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma. Cancer 95: 1637-1643
9. Glenjen N, Mosevoll KA, Bruserud O (2002) Serum levels of angiogenin, basic fibroblast growth factor and endostatin in patients receiving intensive chemotherapy for acute myelogenous leukemia. Int J Cancer 101: 86-94
10. Hamano Y, Zeisberg M, Sugimoto H, Lively JC, Maeshima Y, Yang C, Hynes RO, Werb Z, Sudhakar A, Kalluri R (2003) Physiological levels of tumstatin, a fragment of collagen IV α3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via αVβ3 integrin. Cancer Cell 3: 589-601
11. Hanai J, Gloy J, Karumanchi SA, Kale S, Tang J, Hu G, Chan B, Ramchandran R, Jha V, Sukhatme VP, Sokol S (2002) Endostatin is a potential inhibitor of Wnt signaling. J Cell Biol 158: 529-539
12. Haviv F, Bradley MF, Kalvin DM, Schneider AJ, Davidson DJ, Majest SM, McKay LM, Haskell CJ, Bell RL, Nguyen B, Marsh KC, Surber BW, Uchic JT, Ferrero J, Wang YC, Leal J, Record RD, Hodde J, Badylak SF, Lesniewski RR, Henkin J (2005) Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis and optimization of pharmacokinetics and biological activities. J Med Chem 48: 2838-2846
13. Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Charnsangavej C, Madden T, Davis DW, McConkey DJ, O'Reilly MS, Ellis LM, PLuda J, Hong WK, Abbruzzese JL (2002a) Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 20: 3792-3803
14. Herbst RS, Mullani NA, Davis DW, Hess KR, McConkey DJ, Charnsangavej C, O'Reilly MS, Kim H-W, Baker C, Roach J, Ellis LM, Rashid A, Pluda J, Bucana C, Madden TL, Tran HT, Abbruzzese JL (2002b) Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol 20: 3804-3814
15. Homandberg GA, Williams JE, Grant D, Schumacher B, Eisenstein R (1985) Heparin-binding fragments of fibronectin are potent inhibitors of endothelial cell growth. Am J Pathol 120: 327-332
16. Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson E (2003) Alport's syndrome, Goodpasture's syndrome, and type IV collagen. N Engl J Med 348: 2543-2556
17. Iizasa T, Chang H, Suzuki M, Otsuji M, Yokoi S, Chiyo M, Motohashi S, Yasufuku K, Sekine Y, Iyoda A, Shibuya K, Hiroshima K, Fujisawa T (2004) Overexpression of collagen XVIII is associated with poor outcome and elevated levels of circulating serum endostatin in non-small cell lung cancer. Clin Cancer Res 10: 5361-5366
18. Jin H, Varner J (2004) Integrins: roles in cancer development and as treatment targets. Br J Cancer 90: 561-565
19. Kalluri R (2003) Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 3: 422-433
20. Karumanchi SA, Jha V, Ramchandran R, Karihaloo A, Tsiokas L, Chan B, Dhanabal M, Hanai JI, Venkataraman G, Shriver Z, Keiser N, Kalluri R, Zeng H, Mukhopadhyay D, Chen RL, Lander AD, Hagihara K, Yamaguchi Y, Sasisekharan R, Cantley L, Sukhatme VP (2001) Cell-surface glypicans are low-affinity endostatin receptors. Mol Cell 7: 811-822
21. Kim YM, Hwang S, Pyun BJ, Kim TY, Lee ST, Gho YS, Kwon YG (2002) Endostatin blocks VEGF-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem 277: 27872-27879
22. Kisker O, Becker CM, Prox D, Fannon M, D'Amato R, Flynn E, Fogler WE, Sim BK, Allred EN, Pirie-Shepherd SR, Folkman J (2001) Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 61: 7669-7674
23. Klement G, Kikuchi L, Kieran M, Almog N, Yip T, Folkman J (2004) Early tumor detection using platelet uptake of angiogenesis regulators. Blood 104: 839a
24. Kulke M, Bergsland E, Ryan DP, Clark JW, Enzinger PC, Michelini A, Kinsella K, Fogler W, Venook A, Fuchs C (2003) A phase II open-label, safety, pharmacokinetic and efficacy study of recombinant human endostatin in patients with advanced neuroendocrine tumors. Proc Am Soc Clin Oncol 22: 958a
25. Lee SJ, Jang JW, Kim YM, Lee HI, Jeon JY, Kwon YG, Lee ST (2002) Endostatin binds to the catalytic domain of matrix metalloproteinase-2. FEBS Lett 519: 147-152
26. MacDonald NJ, Shivers WY, Narum DL, Plum SM, Wingard JN, Fuhrmann SR, Liang H, Holland-Linn J, Chen DH, Sim BK (2001) Endostatin binds tropomyosin. A potential modulator of the anti-tumor activity of endostatin. J Biol Chem 276: 25190-25196
27. Maeshima Y, Manfredi M, Reimer C, Holthaus KA, Hopfer H, Chandamuri BR, Kharbanda S, Kalluri R (2001) Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin. J Biol Chem 276: 15240-15248
28. Marneros AG, Olsen BR (2005) Physiological role of collagen XVIII and endostatin. FASEB J 19: 716-728
29. Nyberg P, Xie L, Kalluri R (2005) Endogenous inhibitors of angiogenesis. Cancer Res 65: 3967-3979
30. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane S, Flynn E, Birkhead JR, Olsen BR, Folkman J (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285
31. Olsson A-K, Johansson I, Akerud H, Einarsson B, Christofferson R, Sasaki T, Timpl R, Claesson-Welsh L (2004) The minimal active domain of endostatin is a heparin-binding mutant that mediates inhibition of tumor vascularization. Cancer Res 64: 9012-9017
32. Pezzella F, Pastorino U, Tagliabue E, Andreola S, Sozzi G, Gasparini G, Menard S, Gatter KC, Harris AL, Fox S, Buyse M, Pilotti S, Pierotti M, Rilke F (1997) Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol 151: 1417-1423
33. Plum SM, Hanson AD, Volker KM, Vu HA, Sim BK, Fogler WE, Fortier AH (2003) Synergistic activity of recombinant human endostatin in combination with adriamycin: analysis of in vitro activity on endothelial cells and in vivo tumor progression in an orthotopic murine mammary carcinoma model. Clin Cancer Res 9: 4619-4626
34. Rosner GL, Stadler W, Ratain MJ (2002) Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol 20: 4478-4484
35. Shi W, Teschendorf C, Muzyczka N, Siemann DW (2003) Gene therapy delivery of endostatin enhances the treatment efficacy of radiation. Radiother Oncol 66: 1-9
36. Sudhakar A, Sugimoto H, Yang C, Lively J, Zeisberg M, Kalluri R (2003) Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by αvβ3 and α5β1 integrins. Proc Natl Acad Sci USA 100: 4766-4771
37. Sun Y, Wang J, Liu Y, Song X, Zhang Y, Li K, Zhu Y, Zhou Q, You L, Yao C (2005) Results of a phase III trial of Endostar TM (rh-endostatin, YH-16) in advanced non-small cell lung cancer patients. Proc ASCO 23: 7138a
38. Sund M, Hamano Y, Sugimoto H, Sudhakar A, Soubosakos M, Yerramalla U, Benjamin LE, Lawler J, Kieran M, Shah A, Kalluri R (2005) Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc Natl Acad Sci USA 102: 2934-2939
39. Thomas JP, Arzoomanian RZ, Alberti D, MArnocha R, Lee F, Friedl A, Tutsch K, Dresen A, Geiger P, PLuda J, Fogler W, Schiller JH, Wilding G (2003) Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 21: 223-231
40. 2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity. Cancer Res 65: 3656-3663
41. Van der Schaft DWJ, Seftor REB, Seftor EA, Hess AR, Gruman LM, Kirschmann DA, Yokoyama Y, Griffioen AW, Hendrix MJC (2004) Effects of angiogenesis inhibitors in vascular network formation by human endothelial and melanoma cells. J Natl Cancer Inst 96: 1473-1477
42. Wickström SA, Alitalo K, Keski-Oja J (2003) Endostatin associates with lipid rafts and induces reorganization of the actin cytoskeleton via down-regulation of RhoA activity. J Biol Chem 278: 37895-37901
43. Yang Q, Rasmussen SA, Friedman JM (2002) Mortality associated with Down's syndrome in the USA from 1983 to 197: a population based study. Lancet 359: 1019-1025
44. Yokoyama Y, Ramakrishnan S (2004) Addition of integrin binding sequence to a mutant human endostatin improves inhibition of tumor growth. Int J Cancer 111: 839-848
45. Zorick TS, Mustacchi Z, Bando SY Zatz M, Moreira-Filho CA, Olsen B, Passos-Bueno MR (2001) High serum endostatin levels in Down's syndrome: implications for improved treatment and prevention of solid tumours. Eur J Hum Genet 9: 811-814